Agendia and Genecast Biotechnology Partner to Launch MammaPrint(R) and BluePrint(R) in China
For the first time, early-stage breast cancer patients and their physicians in China can access clinically validated and prospectively proven tests for breast cancer risk of recurrence and molecular subtyping
IRVINE, Calif. and AMSTERDAM and BEIJING, Se... Diagnostics, Personalized Medicine, Oncology, Product Launch Agendia, MammaPrint, breast cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Breast Cancer | Cancer | Cancer & Oncology | China Health | Pharmaceuticals